Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | RXRB | P28702 | 17/20 | 1.00 |
| ▸ | RXRG | P48443 | 17/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | RARG | P13631 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180019 | 0.87 | RXRA (0.76) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17049104 | 0.86 | RXRA (1.00) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL13368670 | 0.85 | RXRA (0.74) | RXRARXRBRXRGCYP26B1 | |
| SCHEMBL13621649 | 0.84 | RXRA (0.73) | RXRARXRBRXRGCYP26B1 | |
| SCHEMBL5180811 | 0.84 | RXRA (0.83) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17053975 | 0.83 | RXRA (0.76) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL5179608 | 0.83 | RXRA (0.76) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL5179870 | 0.80 | RXRA (0.72) | RXRARXRBRXRGPPARGNR1H3 | |
| SCHEMBL17053989 | 0.76 | RXRA (1.00) | RXRARXRBRXRGPPARG | |
| SCHEMBL17049094 | 0.75 | RXRA (0.78) | RXRARXRBRXRGPPARGNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| EP-4334436-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Yeda Research and Development Co. Ltd (IL) | 2024-03-13 | — | — | EP | claimed |
| US-20240074473-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-07 | — | — | US | claimed |
| WO-2022234586-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-11-10 | — | — | WO | claimed |
| US-20090291492-A1 | METHOD FOR FORMING ORGAN | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-11-26 | — | — | US | claimed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | claimed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | disclosed |
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250346631-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| JP-2009215178-A | NEW APPLICATION OF PYRIMIDINE-5-CARBOXYLIC ACID DERIVATIVE AS ANTIOBESTIC AGENT | KOKURITSU IYAKUHIN SHOKUHIN EISEI KENKYUSHO | 2009-09-24 | — | — | JP | disclosed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1180520-B1 | PYRIMIDINE CARBOXYLIC ACID DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005099759-A1 | MEDICINE FOR PREVENTION AND/OR TREATMENT OF ARTERIOSCLEROSIS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-10-27 | — | — | WO | disclosed |
| US-6869959-B1 | Heterocyclic carboxylic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2005-03-22 | — | — | US | disclosed |
| EP-1180520-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346631-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | VIP, TNFSF10, IAPP | RXRA 878/4885RXRB 420/4885RXRG 318/4885 |
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RXRG 3/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | RXRA 2/4885RXRB 3/4885RXRG 1/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | RXRA 18/4885RXRB 10/4885RXRG 26/4885 |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | EZH2, DOT1L, EHMT1 | RXRA 1198/4885RXRB 806/4885RXRG 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.